title: Oral administration of L-arginine decreases blood pressure and increases renal excretion of sodium and water in renovascular hypertensive rats.
abstract: The two-kidney, one-clip renovascular (2K1C) hypertension model is characterized by a reduction in renal flow on the clipped artery that activates the renin-angiotensin system. Endothelium dysfunction, including diminished nitric oxide production, is also believed to play a role in the pathophysiology of this model. Some studies have shown an effect of L-arginine (L-Arg, a nitric oxide precursor) on hypertension. In the present study we determined the ability of L-Arg (7 days of treatment) to reduce blood pressure and alter renal excretions of water, Na+ and K+ in a model of 2K1C-induced hypertension. Under ether anesthesia, male Wistar rats (150-170 g) had a silver clip (0.20 mm) placed around the left renal artery to produce the 2K1C renovascular hypertension model. In the experimental group, the drinking water was replaced with an L-Arg solution (10 mg/ml; average intake of 300 mg/day) from the 7th to the 14th day after surgery. Sham-operated rats were used as controls. At the end of the treatment period, mean blood pressure was measured in conscious animals. The animals were then killed and the kidneys were removed and weighed. There was a significant reduction of mean blood pressure in the L-Arg-treated group when compared to control (129 7 vs 168 6 mmHg, N = 8-10 per group; P<0.05). Concomitantly, a significant enhancement of water and Na+ excretion was observed in the 2K1C L-Arg-treated group when compared to control (water: 13.0 0.7 vs 9.2 0.5 ml/day, P<0.01; Na+: 1.1 0.05 vs 0.8 0.05 mEq/day, respectively, P<0.01). These results show that orally administered L-Arg acts on the kidney, possibly inducing changes in renal hemodynamics or tubular transport due to an increase in nitric oxide formation.
authors.affiliation: Departamento de Ciências Fisiológicas, Centro Biomédico, Universidade Federal do Espírito Santo, Vitória, ES, Brasil.
authors.forename: S A
authors.initials: SA
authors.lastname: Gouvêa
authors.forename: M R
authors.initials: MR
authors.lastname: Moysés
authors.forename: N S
authors.initials: NS
authors.lastname: Bissoli
authors.forename: J G P
authors.initials: JG
authors.lastname: Pires
authors.forename: A M
authors.initials: AM
authors.lastname: Cabral
authors.forename: G R
authors.initials: GR
authors.lastname: Abreu
mesh_terms: D000818:Animals; D001120:Arginine / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D001834:Body Water / Q000378:metabolism; D004195:Disease Models, Animal; D004231:Diuresis / Q000187:drug effects*; D006978:Hypertension, Renovascular / Q000188:drug therapy*; D008297:Male; D009318:Natriuresis / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D012964:Sodium / Q000652:urine*
chemical_list: D001120:Arginine; D012964:Sodium